Joseph P. Lyssikatos net worth and biography

Joseph Lyssikatos Biography and Net Worth

Co-founder, Chief Scientific Officer of Enliven Therapeutics

Joe is a co-founder of Enliven Therapeutics and serves as the Chief Scientific Officer. Prior to co-founding Enliven, Joe served as Vice President of Medicinal Chemistry and DMPK at Biogen, a biotechnology company focused on therapies for neurological diseases. He also worked as an Executive Director at AbbVie, Staff Scientist at Genentech, and Senior Director at Array Biopharma. He began his pharmaceutical career as a medicinal chemist at Pfizer Groton.

Joe has experience in multiple therapeutic areas, including antibiotics, immunology, cancer, and neuroscience. He has led or been a key scientific contributor to over 30 programs, which has resulted in the discovery of more than 15 clinical candidates, most notably: Koselugo™ (selumetinib), Mektovi^®(binimetinib), Tukysa^® (tucatinib), crenolanib, BIIB091, varlitinib tosilate, filanesib, and motolimod. He is a co-inventor or co-author on over 230 issued patents and peer-reviewed publications.

Joe earned a Ph.D. in Chemistry from the University of California, Berkeley and a B.S. in Chemistry from the College of William and Mary.

What is Joseph P. Lyssikatos' net worth?: The estimated net worth of Joseph P. Lyssikatos is at least $30.78 million as of February 6th, 2026. Dr. Lyssikatos owns 740,188 shares of Enliven Therapeutics stock worth more than $30,777,017 as of May 6th. This net worth evaluation does not reflect any other investments that Dr. Lyssikatos may own. Learn More about Joseph P. Lyssikatos' net worth.
How do I contact Joseph P. Lyssikatos?: The corporate mailing address for Dr. Lyssikatos and other Enliven Therapeutics executives is 309 Beacon Street Suite 300 Office 341, Brookline MA, 02446. Enliven Therapeutics can also be reached via phone at 617-927-9989 and via email at [email protected]. Learn More on Joseph P. Lyssikatos' contact information.
Has Joseph P. Lyssikatos been buying or selling shares of Enliven Therapeutics?: Joseph P. Lyssikatos has not been actively trading shares of Enliven Therapeutics during the past quarter. Most recently, Joseph P. Lyssikatos sold 5,000 shares of the business's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $29.04, for a transaction totalling $145,200.00. Following the completion of the sale, the insider now directly owns 740,188 shares of the company's stock, valued at $21,495,059.52. Learn More on Joseph P. Lyssikatos' trading history.
Who are Enliven Therapeutics' active insiders?: Enliven Therapeutics' insider roster includes Rahul Ballal (Director), Rishi Gupta (Director), Richard Heyman (Chairman of the Board of Directors), Benjamin Hohl (Chief Financial Officer and Head of Corporate Development), Samuel Kintz (Co-founder, Chief Executive Officer, and Member of the Board of Directors), Joseph Lyssikatos (Co-founder, Chief Scientific Officer), and Anish Patel (Co-founder and Chief Operating Officer). Learn More on Enliven Therapeutics' active insiders.
Are insiders buying or selling shares of Enliven Therapeutics?: In the last twelve months, insiders at the sold shares 48 times. They sold a total of 481,245 shares worth more than $11,305,844.23. The most recent insider tranaction occured on March, 6th when CFO Benjamin Hohl sold 10,000 shares worth more than $295,800.00. Insiders at Enliven Therapeutics own 25.9% of the company. Learn More about insider trades at Enliven Therapeutics.
Information on this page was last updated on 3/6/2026.

Joseph P. Lyssikatos Insider Trading History at Enliven Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/6/2026	Sell	5,000	$29.04	$145,200.00	740,188
1/20/2026	Sell	20,000	$26.75	$535,000.00	745,188
1/9/2026	Sell	91,198	$27.22	$2,482,409.56	765,188
1/8/2026	Sell	41,302	$24.05	$993,313.10	856,386
12/19/2025	Sell	5,000	$16.84	$84,200.00	897,688
11/19/2025	Sell	12,500	$22.33	$279,125.00	902,688
10/20/2025	Sell	12,500	$22.08	$276,000.00	915,188
9/26/2025	Sell	4,000	$20.25	$81,000.00	927,688
9/23/2025	Sell	1,500	$20.03	$30,045.00	931,688
9/19/2025	Sell	7,000	$19.39	$135,730.00	933,188
8/21/2025	Sell	7,500	$20.01	$150,075.00	940,188
8/19/2025	Sell	5,000	$19.62	$98,100.00	947,688
7/21/2025	Sell	12,500	$22.29	$278,625.00	952,688
6/20/2025	Sell	12,500	$21.40	$267,500.00	965,188
6/3/2025	Sell	7,500	$20.03	$150,225.00	977,688
5/19/2025	Sell	5,000	$16.31	$81,550.00	985,188
5/1/2025	Sell	5,030	$20.07	$100,952.10	992,658
4/21/2025	Sell	5,000	$16.07	$80,350.00	997,688
3/19/2025	Sell	12,500	$20.61	$257,625.00	1,002,688
10/18/2024	Sell	847	$30.00	$25,410.00	1,015,188
10/9/2024	Sell	37,878	$28.16	$1,066,644.48	1,016,035
10/7/2024	Sell	2,707	$27.61	$74,740.27	1,067,180
10/4/2024	Sell	7,522	$27.51	$206,930.22	1,069,887
10/1/2024	Sell	527	$27.54	$14,513.58	1,077,409
8/29/2024	Sell	12,000	$22.49	$269,880.00	1,077,936
7/31/2024	Sell	3,099	$27.56	$85,408.44	1,089,936
7/29/2024	Sell	12,000	$26.70	$320,400.00	1,093,035
4/29/2024	Sell	12,000	$17.92	$215,040.00
4/11/2024	Sell	30,000	$25.04	$751,200.00
4/1/2024	Sell	12,000	$18.60	$223,200.00
2/29/2024	Sell	12,000	$16.42	$197,040.00
1/29/2024	Sell	12,000	$15.85	$190,200.00
12/21/2023	Sell	20	$13.00	$260.00
12/19/2023	Sell	200	$13.00	$2,600.00
11/3/2023	Sell	8,546	$13.08	$111,781.68
9/29/2023	Sell	12,000	$13.62	$163,440.00

Joseph P. Lyssikatos Buying and Selling Activity at Enliven Therapeutics

Enliven Therapeutics Company Overview

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Today's Range

Now: $41.58

$40.72

$42.99

50 Day Range

MA: $36.54

$27.25

$48.11

2 Week Range

Now: $41.58

$14.78

$48.53

Volume

448,283 shs

Average Volume

1,004,878 shs

Market Capitalization

$2.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32